Empirico is a biotechnology startup that stands out for its cutting-edge approach in the realm of genetic medicine. The company’s core mission is captured in its slogan: "Discovering and developing novel siRNA medicines designed to mimic naturally-occurring genetic variants."
Utilizing proprietary technology platforms, Empirico is making significant strides in the creation of siRNA medicines. These innovative treatments aim to replicate genetic variations that are naturally advantageous, thereby addressing common diseases with currently unmet medical needs. The company's strength lies in its exceptional capabilities in human genetics and siRNA chemistry, which are further enhanced through strategic partnerships.
Though the startup's founding date, headquarters, and latest investment details remain unspecified, Empirico offers a rapidly expanding pipeline of both clinical and preclinical programs, indicating a promising trajectory for potential investors in the biotech industry.
